Predict your next investment

HEALTHCARE | Drug Development

See what CB Insights has to offer

Founded Year




Total Raised


Date of IPO


Market Cap


About Ascletis Pharma

Ascletis Pharma (HKG: 1672) is a biotechnology company dedicated to discovering, developing and commercializing new treatments for infectious diseases, such as HCV, HIV and HBV, and cancer. Ascletis is focused on clinical development and commercialization of medicines for the growing Chinese pharmaceutical market.

Ascletis Pharma Headquarter Location

Room 804, Building 1, Xinshuang Shuangcheng Building No. 1785 Jianghan Road, Changhe Street, Binjiang District

Hangzhou, Zhejiang ,


+86 571- 8538-9729

Latest Ascletis Pharma News

Ascletis to Add Oncology Drugs to Infectious Disease and NASH Portfolios

Mar 30, 2021

publication date: Mar 30, 2021 Hangzhou 's Ascletis Pharma announced that it will expand its focus into oncology. The company was founded to bring effective hepatitis C treatments to China at an affordable price. It has accomplished that, and it now plans to combine its two in-licensed FASN inhibitors with two self-discovered anti-cancer drugs, an EGFR anti-angiogenesis candidate (bevacizumab) and a small molecule PD-1 inhibitor. Initially, it will test a combination of ASC40 and bevacizumab in patients with astrocytoma, a cancer of the brain or spinal cord.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ascletis Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ascletis Pharma is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.



5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Ascletis Pharma Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ascletis Pharma Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.